Biogen we to delighted technology for collaboration diseases medicines global were to new Thank of neurological you, announce afternoon, into protein Sandy. with finger engineered develop genomic zinc significance. Yesterday Sangamo's proprietary our
development specificity genes the The and neuroscience. the is ability genomic brain to exciting great new application really switch and medicines off with switch a in in genes precisely to on in of
to delivered alpha currently The collaboration finger activate ST-XXX, using tau targeting targets are Sangamo's ZFP-TFs, at protein selectively regulation adeno-associated in and transcription candidates first genome of product AAVs or genes the factors, desired the effect. function which the pioneering expression to specific repress achieve ST-XXX leverage viruses and therapeutic level which DNA synuclein, zinc the technology,
this genomewide and finger manuscript the proteins models the long-term high a that Medicine technology. provided in of selectivity, proof published Huntington's Sangamo TFs specificity zinc tolerability Nature year, concept Last of disease preclinical detailing in of for
range as can alpha has neurological to allows as therapeutic tuned of applications be a wide our any This or for single repression regulation synuclein ALS it is Allele-selective the within pan-allelic expression also gene and engineered the with levels tau technology potential be type. of ZFP-TF as case such space beyond Huntington's many including cell neuroscience programs. in or applications gene areas targets tunable disease for to
other diseases the benefits Sangamo's In is Alzheimer's strategies differentiated of toxic accumulation the several misfolded as neurodegenerative targeting important difficult. neurons, of example, is different ZFP-TF under that such investigation. case these currently and of to proteins therapeutic are over all and technology and treatment there proteins provide incredibly Parkinson's for the forms
the DNA these were as are and disease at drivers the by there address upstream by also copies multiple of the level. to the key of the source, and expression in we target several contrast, ZFP-TF, however, It forms. repressing they challenging their protein using with both In able the disease targeting come molecules the at complexity RNA the RNA is to
of the symptoms. cell brain and and tau Furthermore, the toxic one-time expression other therapeutic neuronal an administration of many to accumulation the of ZFP-TFs Alzheimer's disease currently the other a the of prospects are under to advantages protein modalities restrict tauopathies, that clinical over potential specific populations important In loss investigation. that is case AAV clinical progressive of in has can linked
neuron been may of Reducing have tau expressed the a and role of reducing or and cellular aggregation in potential models disease tau shown to of animal the even alpha deficits halt slow play to associated synuclein been Similarly, within brain to alpha with synuclein amount benefit Parkinson's to tauopathies. has of Consequently, the Parkinson's the expression has in the of or shown misfolding total in central respectively. Alzheimer's disease disease. progression the provide
would but of I'm excited completely medicine a disease it to a The the these whole unlocks also both symptoms arrests new this diseases of or slows treatment area treatments that clearly into CNS. the compelling progression disease and targets current immensely the marketed really about be target pathology. very because additionally collaboration have
highly synuclein. of of AAV deliver demonstrated repression efficiently tau to ability that and that specific, synuclein ST-XXX vectors Preclinical alpha targeted studies to in and ST-XXX and tunable have targeted the of results or alpha are tau potent, ZFP-TFs
brain the of targeted by non-human ZFP-TFs. demonstrated significant year data expression Sangamo administration last Indeed, of presented tau the in reduction preclinical primate following
levels also December system. in of Day R&D We last ex-vivo York than alpha cell XX% half data than the culture synuclein in City, tested our New that greater by at showed more preclinical the reduced which total ZFP-TFs presented
them to to and studies. progress We assets are IND-enabling very further these Biogen to to excited develop with work
the genes. research vectors neurological Under Sangamo delivery therapeutically collaboration our relevant early and Biogen, of development with activities will the lead target ZFP-TFs the take aimed that of at terms AAV proprietary on
Following also this IND-enabling interactions responsibility regulatory preclinical commercialization. sole and phase, development, will development studies, assume clinical Biogen for the
trials clinical some our regulatory necessary the cell into approvals the on a progressing X to now and clinical updates. throughout lead Phase advance and ended to therapy strong Phase note a asset gene securing Pfizer SP-XXX program programs into Turning We X/X year. XXXX with additional
Hemophilia SB-XXX sustained The presented treatment. ASH with levels potential tolerated addition to annual therapy; Starting in that meeting in the transfer December. pleased generally we the for the of following data the Phase recent program X/X with Factor the Pfizer, well and suggest to was A gene was VIII SB-XXX were that showed data at
observe accumulate. We will the continue to the as data durability follow-up
Moving currently in has six and in currently ST-XXX gene owned patients now disease. clinical wholly our the sites therapy Fabry opened U.S. We're which screening to STAAR the follow-on for trial,
first The from received Agency initiated designation Medicines week. the orphan in London was site ST-XXX in European drug January. this European
year, study in patients Sanofi. X/X vivo thalassemia beta presented cell with Phase transfusion-dependent THALES ST-XXX, last therapy from partnership an preliminary gene-edited in we ASH the with information ex At assessing
profile data the and treatment. follow to understand to continue potential safety clinical the benefits the will of We
in PRECIZN-X treatment cell of sickle Also our trial payment. Phase regimen to related the uses in for therapy evaluating which Sangamo ex Sanofi, cell received dosed finger patient manufacturing a nuclease and as process the with disease BIVVXXX, gene-edited for milestone the cells was zinc with differs. mediated identical first million vivo mobilization partnership BIVVXXX the patient's an editing a $X.X ST-XXX X/X
in is with G-CSF as population. is Plerixafor in contraindicated as combination disease beta sickle compared plerixafor with in thalassemia G-CSF for cell patient alone used this
trial clinical happy the in study received cell we're to HLA-AX of X/X that authorization TXXXX, approvals, U.K. number mismatch human on CAR-Treg therapy to clinical Moving we and STEADFAST our now recently application regulatory say Phase in for kidney the transplantation. in a including first
an We trial allogeneic continue KITE-XXX, work therapy advance with CAR-T our clinical to closely oncology into the Kite, will collaborator, year. anti-CDXX this as they
and encouraging the we on the is clinical to of creating FDA's developments medicine Finally, pathways treatment continuing promise to FDA pleased progress as see of this new much for recognizes immensely in interactions that that mention genomic pipeline. our guidance look We was further with I published January. gene develop regulatory modality. therapy and we forward that very the is manufacturing FDA products therapy our to would like and the gene certainly It were
an now Sung I to Sung? over financial the results. for it turn overview of will
